Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Investing Activities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash from Investing Activities for 11 consecutive years, with -$72.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities changed N/A to -$72.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$72.3 million, a N/A change, with the full-year FY2025 number at -$72.9 million, down 364185.28% from a year prior.
  • Cash from Investing Activities was -$72.2 million for Q4 2025 at Crescent Biopharma, down from -$132561.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$1.0 in Q4 2022 to a low of -$72.2 million in Q4 2025.
  • A 5-year average of -$4.8 million and a median of -$5102.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 99.96% in 2022, then crashed 80000.0% in 2023.
  • Crescent Biopharma's Cash from Investing Activities stood at -$2447.0 in 2021, then surged by 99.96% to -$1.0 in 2022, then plummeted by 80000.0% to -$801.0 in 2023, then crashed by 828.71% to -$7439.0 in 2024, then plummeted by 970366.46% to -$72.2 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Cash from Investing Activities are -$72.2 million (Q4 2025), -$132561.0 (Q2 2025), and -$7439.0 (Q1 2024).